| |
|
| |
 |
 |
 |
| |
|
| |
|
| |
|
| |
Company
Profile |
| |
|
| |
The development of a new drug
costs roughly 800 M.USD. This huge investment has to cover both
the development of the drug itself and the cost of unfruitful work.
Dead-ends can represent up to 80% of the total cost of a successful
drug. Major challenges in the drug development process are (1) to
reduce high failure rates due to faulty candidate selection and
false positives and (2) to identify all the potential candidates
among the false negatives.
There are thus great potential savings to be realized by making
development more efficient. To help make these savings, genOway
designs, develops and markets technologies and proprietary innovative
genetically modified biological models. These solutions aim to increase
the predictability and throughput of research in target validation,
drug screening and pharmacological - toxicological studies.
|
| |
|
 |
 |
| |
Board
of Directors |
| |
|
| |
|
| |
|
| |
Alexandre
Fraichard - MBA HEC CEO
French. Earned his Ph.D. at the
Ecole Normale Supérieure de Lyon
in Molecular and Cellular Biology in 1997. Worked for five years
on animal models at the ENS where he produced the first model of
hypothyroidism and co-founded the Transgenetic Center.
Did an MBA (1998-1999) at the HEC
business school (Paris, France) and co-founded genOway in 1999.
|
| |
 |
| |
Gilles
de Poncins - MBA HEC - CFO
French. Graduated from the
Institut d'Etudes Politiques in Paris. Twelve years
experience in finance. Head of the risk management department at
Renault Crédit International for three years. Investment
manager in corporate finance at Qualis (1994 1998). Qualis
is a private holding company that raised 300 million FRF in 1996.
CFO of Sofecome, a French company involved in outsourcing (1996
1998). Did an MBA (1998-1999) at the HEC
business school (Paris, France) and co-founded genOway
in 1999.
|
| |
 |
| |
Michel
G. Lurquin
Belgian. Former Director & Vice President
Europe for Technical Operations at SmithKlineBeecham.
Current Head of
UCBP Global Technical Operations,
covering all manufacturing and supply activities worldwide as well
as chemical and pharmaceutical development.
Former Expert with the
EBRD (European Bank for Reconstruction
and Development). During his career with SB filled a number of positions
in Regulatory, Quality and Technical Operations. Actively participating
in the development of two other start-ups in the healthcare sector;
Bioprofile
as a member of the Strategic Committee, Cecami HT as a non-executive director and BioMethodes as associate and Non Executive Director. As part of his assignments with the EBRD, he is also a
non-executive director of
ZAO Katren Pharmaceuticals (Russia).
|
| |
 |
| |
Jean-Claude
Lévêque
French. Represents
DASSAULT DEVELOPPEMENT.Graduated from
HEC and has an MBA in international finance. During time with the
CIC (Credit Industriel et Commercial) between 1984 and 1986 originated
the first FCPR in France. In 1990 joined Innovacom, an investment
fund of France Telecom specialized in financing high-tech start-ups.
From 1997 to 1998, Senior Vice-President in charge of foreign merger
and acquisition operations. Member of the board of Vision Numeric,
Decan, Arche Communications, Business Objects and Infovista.
Joined Dassault Developpement in 1998 as partner.
Secretary of the French Association for the Development of Cellular
and Vascular Biology.
|
| |
 |
| |
Jean-Claude Pignol
French, former VP of TECHNIP, French company involved in engineering. Has a 25 years experience in the management of small industrial companies in international environment.
|
| |
 |
 |
 |
|
Advisors |
| |
|
| |
 |
|
 |
Patent attorney M. Warcoin
CEO of Cabinet
Regimbeau, a leading European patent attorney is advising
the company on its intellectual property policy including
patents, licensing out and licensing in.
|
 |
Corporate advisor Cabinet
Mesny (Paris) and Bird&Bird
(Paris) are advising the company on corporate and shareholder
relations.
|
|
| |
|